Results 161 to 170 of about 785,669 (310)

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Humanized antibody-drug conjugates for Somatostatin receptor 2 (SSTR2)-positive tumor treatment. [PDF]

open access: yesMol Cancer Ther
Zhou Z   +9 more
europepmc   +1 more source

Validation of a High‐Throughput Fluorescent Capillary Electrophoresis Sodium Dodecyl Sulfate Method for Monoclonal Antibody Size Heterogeneity Assessment

open access: yesELECTROPHORESIS, EarlyView.
Validation of an LED fluorescence‐based parallel CE‐SDS method for monoclonal antibody size heterogeneity analysis, demonstrating specificity, accuracy, robustness, and precision (RSD < 1%, for monomeric purity and glycosylation). The method provides established UV‐based results while offering greater sensitivity, baseline stability, and substantially ...
Kyle D. Luttgeharm   +3 more
wiley   +1 more source

Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3. [PDF]

open access: yesMAbs
Genest M   +13 more
europepmc   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

Autonomous Nanomedicine: Closing the Biological Validation Gap

open access: yesExploration, EarlyView.
Delivery of nanoparticles to tumors has not improved in over fifteen years, and biological testing remains slow and separate from formulation design. This review proposes adding a Biology step to the design cycle, using organ chips and patient‐derived organoids, and assesses the readiness of each required technology.
Yan Jun Lin, Izabella Komperda
wiley   +1 more source

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy. [PDF]

open access: yesiScience
Li B   +10 more
europepmc   +1 more source

A Brief Chronicle of Antibody Research and Technological Advances

open access: yes
This review briefly traces the historical development of antibody research and related technologies. The path from early perceptions of immunity to the emergence of modern immunotherapy has been marked by pivotal discoveries and technological advances ...
Kazutaka Araki, Ryota Maeda
core   +1 more source

Home - About - Disclaimer - Privacy